Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia
- PMID: 35964658
- DOI: 10.1016/j.ejphar.2022.175174
Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia
Abstract
Background: Gastrointestinal cation exchangers that can bind potassium in the gut, including sodium polystyrene sulfonate (SPS), calcium polystyrene sulfonate (CPS), patiromer and sodium zirconium cyclosilicate (SZC), are emerging medications for the treatment of hyperkalemia with chronic kidney disease (CKD). However, which might be the best alternative for patients with chronic kidney disease and hyperkalemia remains disputed.
Methods: We performed this systematic review and network meta-analysis with the Bayesian approach to conduct direct and indirect comparisons among potassium binders regarding their efficacy and safety. The surface under the cumulative ranking curve analysis (SUCRA) was used to calculate the best intervention for each outcome.
Results: All four potassium binders had a promising effect regarding potassium reduction. SPS had favorable efficacy and safety for short-term use (MD: -0.94; 95% CIs: -1.4 to -0.48; SUCRA = 94.69%), but long-term treatment required strict dose control and assessment of gastrointestinal conditions. CPS had a positive effect on reducing potassium, and could especially maintain the serum potassium concentration in patients receiving renin-angiotensin-aldosterone system inhibitors (RAASi). Patiromer might reduce all-cause mortality in CKD patients with hyperkalemia and have a positive effect on potassium-lowering, though it had significant gastrointestinal adverse effects. SZC had a potassium-lowering effect in both the short-term and long-term, and can be a promising long-term treatment for the hyperkalemia in CKD patients, especially in combination with RAASi.
Conclusion: These four potassium binders had their own advantages and disadvantages, and the medication should be selected according to the clinical situation of the patient.
Keywords: Calcium polystyrene sulfonate (CPS); Chronic kidney disease; Hyperkalemia; Patiromer; Sodium polystyrene sulfonate (SPS); Sodium zirconium cyclosilicate (SZC).
Copyright © 2022 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare no potential conflicts of interest concerning the research, authorship, and/or publication of this article.
Similar articles
-
Renin-Angiotensin-Aldosterone System Inhibitor Dosing After Initiation of Outpatient Sodium Zirconium Cyclosilicate Therapy: The GALVANIZE RAASi Real-World Evidence Study.Adv Ther. 2025 Aug;42(8):3960-3977. doi: 10.1007/s12325-025-03254-z. Epub 2025 Jun 18. Adv Ther. 2025. PMID: 40531443 Free PMC article.
-
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials.J Pharm Pharm Sci. 2023 Dec 20;26:11892. doi: 10.3389/jpps.2023.11892. eCollection 2023. J Pharm Pharm Sci. 2023. PMID: 38173862 Free PMC article.
-
Novel Potassium Binders in Reduction of Hyperkalemia and Optimization of RAAS Inhibitors Treatment in Patients with Chronic Kidney Disease or Heart Failure: A Systematic Review and Meta-analysis.Drugs. 2025 Aug;85(8):1013-1031. doi: 10.1007/s40265-025-02198-6. Epub 2025 Jun 21. Drugs. 2025. PMID: 40542996 Free PMC article.
-
Comparison of Three Potassium Binders in Patients With Acute Hyperkalemia.Cureus. 2025 Jun 28;17(6):e86922. doi: 10.7759/cureus.86922. eCollection 2025 Jun. Cureus. 2025. PMID: 40726889 Free PMC article.
-
Sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for treatment of hyperkalemia in hemodialysis patients: a randomized clinical trial.BMC Nephrol. 2025 May 6;26(1):227. doi: 10.1186/s12882-025-04129-9. BMC Nephrol. 2025. PMID: 40329202 Free PMC article. Clinical Trial.
Cited by
-
A Case of Sigmoid Colon Perforation Associated with Sodium Zirconium Cyclosilicate in a Patient with Advanced Rectal Cancer.Surg Case Rep. 2025;11(1):24-0123. doi: 10.70352/scrj.cr.24-0123. Epub 2025 Mar 11. Surg Case Rep. 2025. PMID: 40115217 Free PMC article.
-
Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere!Clin Kidney J. 2023 Apr 21;16(8):1221-1225. doi: 10.1093/ckj/sfad090. eCollection 2023 Aug. Clin Kidney J. 2023. PMID: 37529653 Free PMC article.
-
Evaluation of the introduction of novel potassium binders in routine care; the Stockholm CREAtinine measurements (SCREAM) project.J Nephrol. 2024 May;37(4):961-972. doi: 10.1007/s40620-023-01860-0. Epub 2024 Jan 18. J Nephrol. 2024. PMID: 38236474 Free PMC article.
-
Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast….Clin Kidney J. 2023 Apr 21;16(8):1213-1220. doi: 10.1093/ckj/sfad089. eCollection 2023 Aug. Clin Kidney J. 2023. PMID: 37529644 Free PMC article.
-
Safety and efficacy of sodium zirconium cyclosilicate for the management of acute and chronic hyperkalemia in children with chronic kidney disease 4-5 and on dialysis.Pediatr Nephrol. 2024 Apr;39(4):1213-1219. doi: 10.1007/s00467-023-06176-6. Epub 2023 Oct 20. Pediatr Nephrol. 2024. PMID: 37857905
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical